In order to directly determine the amount of label exchange that occurs in the tricarboxylic cycle from labeled alanine and lactate after the ingestion of a glucose load [1-13C]glucose was administered by continuous intraduodenal infusion to awake catheterized rats to achieve steady state jugular venous glycemia (160 mg/dl) for 180 min. Liver was freeze-clamped at 90 and 180 min, and perchloric acid extracts of the liver were subjected to 13C and 1H nuclear magnetic resonance analysis. Dilution in the oxaloacetate pool was determined by comparing the intrahepatic 13C enrichments of C2, C3 positions of glutamate with the C2, C3 positions of alanine and lactate. In addition steady state flux equations were derived for calculation of relative fluxes through pyruvate dehydrogenase/TCA cycle flux and pyruvate kinase flux/total pyruvate utilization. After glucose ingestion in a 24-h fasted rat direct conversion of glucose was responsible for 34% of glycogen. The intrahepatic dilution factor for labeled pyruvate in the oxaloacetate pool was 2.4. Using this factor, alanine and lactate contributed approximately 55% to glycogen formation. Pyruvate dehydrogenase flux ranged between 24 and 35% of total acetyl-coenzyme A (CoA) production and pyruvate kinase flux relative to total pyruvate utilization was approximately 40%.
Quantitative Analysis of Glycogen Repletion by Nuclear Magnetic Resonance Spectroscopy in the Conscious Rat

Gerald L. Shulman, Luciano Rossetti, Douglas L. Rothman, James B. Blair, and Douglas Smith
Division of Diabetes/Endocrinology, Departments of Medicine and Molecular Biology and Biophysics, Yale University, New Haven, Connecticut 06511; Department of Biochemistry, West Virginia University Medical Center, Morgantown, West Virginia 26506; Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts 02114

Abstract

In order to directly determine the amount of label exchange that occurs in the tricarboxylic cycle from labeled alanine and lactate after the ingestion of a glucose load ([1-13C]glucose was administered by continuous intraduodenal infusion to awake catheterized rats to achieve steady state jugular venous glycemia (160 mg/dl) for 180 min. Liver was freeze-clamped at 90 and 180 min, and perchloric acid extracts of the liver were subjected to 13C and 1H nuclear magnetic resonance analysis. Dilution in the oxaloacetate pool was determined by comparing the intrahepatic 13C enrichments of C2, C3 positions of glutamate with the C2, C3 positions of alanine and lactate. In addition steady state flux equations were derived for calculation of relative fluxes through pyruvate dehydrogenase/TCA cycle flux and pyruvate kinase flux in total pyruvate utilization.

After glucose ingestion in a 24-h fasted rat direct conversion of glucose was responsible for 34% of glycogen. The intrahepatic dilution factor for labeled pyruvate in the oxaloacetate pool was 2.4. Using this factor, alanine and lactate contributed ~ 55% to glycogen formation. Pyruvate dehydrogenase flux ranged between 24 and 35% of total acetyl-coenzyme A (CoA) production and pyruvate kinase flux relative to total pyruvate utilization was ~ 40%.

Introduction

There is increasing evidence that the majority of hepatic glycogen repletion after an oral glucose load in rat and man occurs via a gluconeogenic process (1–8). It has been hypothesized that lactate and alanine are the primary gluconeogenic precursors for glycogen formation (2, 4–6). In a previous study using nuclear magnetic resonance spectroscopy (NMR),1 we estimated that a minimum of 10–28% of newly formed glycogen was derived from alanine/lactate (6). Quantitative contribution of these precursors to glycogenesis has been difficult to determine due to the exchange of carbon label in the oxaloacetate (OAA) pool, however, which serves as a common intermediate both in the gluconeogenic pathway and in the tricarboxylic (TCA) cycle (9–11).

To directly determine the amount of label exchange that occurs in the TCA cycle from labeled alanine and lactate after ingestion of a glucose load, [1-13C]glucose was administered (99% enriched) by constant intraduodenal infusion, and the 13C enrichments examined in intrahepatic glutamate, alanine, and lactate under steady state conditions. If the enrichment in carbon positions 2 and 3 of OAA could be determined, it would be possible to directly quantify the dilution of label in the OAA pool. Presently, this is not possible to do by 13C-NMR because of the very low intracellular concentration of this compound. However, the enrichment in carbon positions 2 and 3 of glutamate can readily be determined using 13C-NMR. Since glutamate is believed to be in equilibrium with alpha-ketoglutarate (1a), the ratio of label in the C2, C3 positions of alanine/lactate to the C2, C3 of glutamate during steady state should yield an index to the amount of label exchange that occurs when labeled alanine and lactate pass through the oxaloacetate pool. It is important that this dilution factor can be determined sequentially throughout the postcibal period. This dynamic assessment is crucial because intracellular enzymatic activity (i.e., pyruvate dehydrogenase, pyruvate kinase, etc.) may change following glucose ingestion and thus alter the dilution factor (11).

Another advantage of the present study design is that it allows in vivo quantitation of the relative fluxes through pyruvate dehydrogenase/TCA cycle flux and pyruvate kinase total pyruvate utilization. If the enrichments in the different carbon positions of glutamate, alanine, and lactate under steady state conditions are known, a series of inflow = outflow equations can be developed as described (11, 13–16) to quantitate the relative fluxes of pyruvate dehydrogenase/TCA cycle flux and pyruvate kinase total pyruvate utilization in vivo in a conscious, unstressed rat (see Appendix).

Methods

Animals. Male Sprague-Dawley rats weighing between 250 and 330 g purchased from Hilltop Lab Animals (Chatsworth, CA) were used. They were maintained on standard rat chow (Ralston-Purina Co., St. Louis, MO) and were housed in an environmentally controlled room with a 12-h light/dark cycle. 1 wk before the study an intravenous jugular catheter, extending to the right atrium, and an intraduodenal catheter were implanted. The catheters were filled with heparin/polyvinylpyrrolidone solution, sealed, and tunneled subcutaneously around the side of the neck to the back of the head. The catheters were externalized through a skin incision through the back of the neck. Only those animals that were active and eating normally within 36 h after the surgery were used. All rats were fasted 24 h before the study to deplete liver glycogen. At 0900 hours on the day of the study a prime- (0.7 g/kg) constant (35 mg/
kg ∙ min) infusion of [1-13C]glucose (99% enriched, 15 g/dl) was begun via the duodenal catheter and continued throughout the study. The [1-13C]glucose meal was also labeled with [3-13H]glucose (0.10 μCi/min) (n = 5) or [1-13C]glucose (0.20 μCi/min) (n = 4) to monitor the initial time course and constancy of the plasma [13C]glucose and [13C]lactate specific activities. During the intraduodenal glucose infusion, the animals were allowed to roam freely in their cages. Blood samples for plasma glucose, [13C]glucose and [13C]lactate specific activities were taken at 5–min intervals during the first 60 min of the study and at 15–30–min intervals thereafter, so that a timed average enrichment for glucose and lactate could be calculated. The average blood sample was usually < 200 μl and the blood volume was maintained by transfusing the animal with blood taken from a litter mate as previously described (17). Six rats were killed at 90 min after the start of the glucose infusion and five rats were killed after 180 min. At the time of death, animals were injected with 2% sodium thiamylal (Biotal, Bio-Centric, St. Joseph, MO) (1 ml/kg body wt). The abdomen was quickly opened and a portal vein blood sample was taken. The liver was then freeze-clamped with aluminum tongs precooled to −77°C with liquid nitrogen and weighed. The time from the injection of the anesthetic until freeze clamping of the liver was < 60 s. All tissue samples were frozen at −30°C for subsequent analysis. A group of four control animals were treated in an identical fashion (i.e., diet, housing, catheter insertion, 24-h fast, sacrifice, etc.). In this group no glucose was administered and liver samples were obtained for determination of glycogen concentration as described above.

**Analytical procedures**

Glycogen concentrations in plasma and tissue extracts were determined using a Beckman glucose analyzer (Beckman Instruments, Inc., Palo Alto, CA) and plasma insulin by radioimmunoassay using porcine insulin standards. [13C]glucose and lactate in plasma were quantitated as previously described (6, 18). [13C]lactate in plasma was quantitated by an ion exchange procedure where 50 μl of plasma was added to a pencil column containing 1 ml bed volume of AG-2-X8 acetate (100–200 meshes, Bio-Rad Laboratories, Richmond, CA). The column was washed with 4 ml H2O and acidified with 0.8 ml of 1 N HCl. The lactate was then eluted with 4 ml of 1 N HCl and collected in a scintillation vial to which 15 ml of ScintiVerse II (Fisher Scientific Co., Fair Lawn, NJ) was added and the [13C] counts in the sample were quantitated in a β-liquid scintillation counter. This procedure routinely gave recoveries > 95% for [13C]lactate and removed > 95% of [13C]glucose and [13C]alanine. Liver extracts were made using 0.9 N perchloric acid (PCA) and 99% ethanol to precipitate the glycogen. The glycogen from the PCA pellet was then extracted and digested to glucose as previously described (6).

Lactate, alanine, and glycogen from the previously described experiments, aspartate, were semipurified from the PCA liver extract by means of a (0.9 × 150 cm) Dowex-50 (200–400 mesh) column equilibrated with 0.1 M ammonium formate, pH 3.0 as previously described (19). The alanine and lactate fractions were then lyophilized, brought up in 99.3% D2O and subjected to NMR analysis to determine their 13C fractional enrichment in the C3 position. The fractions were then combined along with the glutamate and aspartate fractions and subjected to 13C-NMR analysis to determine the relative 13C percent labeling in the different positions of alanine, lactate, glutamate, and aspartate. Amino acid analysis was then performed on the same sample by an automated ion exchange chromatographic technique (Dionex 500, Dionex Corporation, Sunnyvale, CA) with an L6 column and lithium citrate buffer to calculate the absolute enrichment of the different positions (Eq. 2).

**NMR methodology.** 13C-NMR spectra of glucose and the combined samples of semipurified alanine, lactate, glutamate, and aspartate obtained from the PCA extracts of liver described above were taken at 125.76 MHz in a spectrometer (WM 500, Bruker Instruments, Inc., Billerica, MA). The samples were placed in standard 5-mm NMR tubes and the spectra were obtained using a standard 5-mm 13C-NMR probe. A 45° pulse was repeated every 3 s for 1–2 h (3,600–10,000 scans). Spectra were acquired with 4,096 data points over a sweep width of 10,000 Hz centered at 45 parts per million (ppm) (relative to β-D-glucose C-1 at 96.8 ppm) (0.205 ms acquisition time). Broad band proton dose-coupling (2–5 W) centered 1 ppm upfield from water was on only during the acquisition time to avoid the development of the nuclear Overhauser effect. The spectral parameters used allowed the intensities C1-C6 of glucose, C2, C3 alanine, C2, C3 lactate, C2, C3, C4 glutamate, and C2, C3 aspartate resonances to be compared without T1 (relaxation time) and nuclear Overhauser effect corrections. Small corrections were made for off-resonance effects. The carbons groups of alanine, lactate, glutamate, and aspartate were not quantitated since under the conditions of our spectra acquisition these groups were not fully relaxed due to their long T2’s. Resonance intensities were determined by computer integration and by manually cutting out and weighing plotted resonances; both methods yielded similar results. All of our spectra had an average signal to noise ratio > 25 to 1, which gave a maximum variability of peak quantitation of ±5%.

The 13C-fractional enrichment of the C-1 position of each glucose sample was determined from 1H-NMR spectra at 360.13 MHz in a standard 1H-NMR probe. A 45° pulse angle (3 μs) with a 10-s relaxation delay was used. During the relaxation delay, the water and deuterium (HDO) resonance was saturated with a single radio frequency field of 50 mW (20). Spectra were acquired with a sweep width of 5,000 Hz centered at the HDO resonance in 8192 data points (0.819 ms acquisition time). Samples were heated to 340°C to shift the HDO resonance upfield from the C-1 proton resonance of alpha-D-glucose.

The 13C-fractional enrichment of portal vein plasma C-1 glucose, and C-3 lactate were determined from 1H-NMR spectra using a homonuclear double resonance spin echo difference sequence (21, 22). A 10-s relaxation delay was used for the glucose and a 15-s delay for lactate and alanine determinations. During the relaxation delay, the HDO resonance was saturated with a 50-mW single radio frequency field (20). During the spin echo/γ delay (136 ms for glucose, 68 ms for lactate and alanine), single frequency 1H-decoupling was applied at 50 mW. All other spectral parameters were as described above. The spectral parameters used allowed the intensities of the proton resonances from protons bonded to 13C- and 12C-nuclei to be compared without T1 or T2 corrections. The 13C-fractional enrichment of C3 Alanine (A3) and C3 lactate (L3) obtained from the PCA extracts of liver were determined by 1H-NMR at 500 MHz in the Bruker WM 500 spectrometer. The samples were placed in a standard 5 mm NMR tube and the spectra were obtained using a standard 5 mm 1H-NMR probe. A 45° pulse was repeated every 3 s for 2–4 h (2,400–4,800 scans). Spectra were acquired with 4096 data points over a sweep width of 5,618 Hz centered at 9,032 Hz.

**Materials**

[1-13C]Glucose (99% enriched) was purchased from Cambridge Isotope Laboratories (Cambridge, MA) and [1-13C]glucose and [3-13H]glucose from New England Biolabs (Boston, MA).

**Calculations**

The 13C labeling and correction for the small amount of unenriched glycogen initially present for each of the six glucose carbon peaks was computed as previously described (6).

The percent glycogen synthesized by the direct pathway was determined by the following equation:

\[
\text{Percent glycogen synthesized via direct pathway} = \left( \frac{\text{GL1} - \text{GL6}}{\text{GL1p}} \right) \times 100 \times 0.80 \tag{1}
\]

where GL1 and GL6 represent the 13C atom percent excess (APE) in positions one and six of glucose in glycogen at the end of the study, GL1p represents the APE in position one of portal vein glucose. For these calculations enrichments of glucose and alanine/lactate were adjusted for the time it took to reach steady state. For glucose it required ∼60 min and for alanine/lactate it required ∼100 min after the start of the glucose infusion before a steady state plasma enrichment/specific activity of each of these compounds was achieved. During these initial time intervals an average enrichment/specific activity was calculated by integrating the area under the initial time course from 0 to 135 min for
\[ ^{3}H \text{glucose and } ^{14}C \text{lactate specific activities (Fig. 1) and time averaged with the steady state enrichment/specific activity during the remainder of the study. From these calculations the following adjustments were made: for } [1\text{-}^{14}C] \text{glucose the adjustment was } 0.80\pm0.05 (n=5) \times pv [1\text{-}^{14}C] \text{glucose enrichment (APE)}; \text{for } [3\text{-}^{14}C] \text{alanine/lactate the adjustment was } 0.69\pm0.04 (n=4) \times \text{[intrahepatic } [2\text{-}^{14}C] \text{ala/lac (APE)} + [3\text{-}^{14}C] \text{ala/lac (APE)].} \]

[where APE = total $^{13}$C enrichment $- 1.1\%$ (natural $^{13}$C abundance)]

To calculate the absolute $^{13}$C enrichments in the different positions of glutamate from the relative $^{13}$C enrichments in alanine, lactate, glutamate, and aspartate, the following formula was used:

\[ ^{13}C_{3} \text{ alanine enrichment} \times \frac{[^{13}C \text{glutamate PI}]}{[^{13}C \text{alanine PI}]} \times \frac{[^{13}C \text{alanine}]}{[^{13}C \text{alanine}] - [^{13}C \text{alanine}] \times \text{(DF)}} \]

where $^{13}C_{3}$ alanine is the enrichment in the C3 position of alanine as determined by $^{13}$C-NMR and [alanine] and [glutamate] are the concentrations of the respective amino acids sampled in the sample as determined by amino acid analysis. $^{13}$C(Glutamate PI) is the $^{13}$C-NMR peak integral for the particular carbon position (i.e., C2, C3, or C4) in glutamate, $^{13}C_{3}$ alanine PI is the $^{13}$C-NMR peak integral for the C3 position in alanine. The absolute enrichments for the individual enrichments of aspartate were calculated in the same way.

The dilution factor (DF) for alanine and lactate as they traverse the oxaloacetate pool was calculated as follows:

\[ (DF) = \frac{A2/L2 + A3/L3}{G2 + G3} \times 100 \]

where A2/L2, A3/L3, and G2, G3 represent the $^{13}$C APE for those respective positions in alanine/lactate (averaged) and glutamate.

To calculate the amount of glycogen synthesized via the indirect pathway from alanine/lactate, the following formula was used:

Percent glycogen synthesized from ala/lac

\[ \frac{(GL5 + GL6) \times DF \times 100}{A2/L2 + A3/L3 \times 0.69} \]

where GL5 and GL6 are the $^{13}$C APE in the fifth and sixth position of the glucose molecule and A2/L2 and A3/L3 are the average $^{13}$C APE for intrahepatic alanine/lactate in the C2 and C3 positions and DF is the dilution factor as described in Eq. 3 all averaged between 90 and 180 min. The individual enrichments for G5 and G6 are used instead of 2 $\times$ G5 to take into account the asymmetry of label in OAA due to the incomplete equilibration between malate and fumarate (14).

Equations for the relative carbon flux through pyruvate dehydrogenase compared to the TCA cycle and through pyruvate kinase compared to total pyruvate utilization are shown below. The derivation of these equations was based upon the assumption of steady state conditions for glutamate and can be found in Appendix:

\[ \text{Pyruvate dehydrogenase flux} = \frac{A4}{G2/L3} \]

\[ \text{Pyruvate kinase flux} = \frac{A2/L2}{G2 + G3} \]

where G2, G3, A4, and A2/L2, A3/L3 are the average APE for the respective positions in glutamate or alanine/lactate.

Data in the text, tables, and figures are given as mean values ± SEM. Statistical comparisons were made using the two-tailed Student t test.

**Results**

Fig. 1 shows the time course for the jugular venous glucose and lactate concentrations (a) and [3-$^{3}$H]glucose and [14$^{14}$C]lactate specific activities (b) after the intraduodenal infusion of glucose labeled with 1-$^{13}$C and either [3-$^{3}$H]glucose or [1-$^{14}$C]glucose.

During the basal period, the plasma glucose concentration was 105±3 mg/dl and rose to a plateau of 160 mg/dl by 30 min. The mean portal vein glucose was 202±8 mg/dl at 90 min and 194±6 mg/dl at 180 min. The mean plasma lactate concentration at 10 min was 0.74±0.12 mM and rose to a plateau value of 1.51±0.20 mM by 90 min. The initial specific activity of glycogen was 0.43±0.1 g/100 mg and remained constant until the end of the experiment. The [14$^{14}$C]lactate specific activity reached a plateau by 60 min and remained constant for the duration of the study. The mean plasma insulin during the basal period was 11±2 μU/ml (n = 5) and rose to 42±12 μU/ml at 15 min and remained constant for the remainder of the 180-min glucose infusion. The mean portal vein insulin concentration was 67±25 μU/ml at the end of the study. Fasting liver glycogen concentration was 0.43±0.1 g/100 mg (n = 4) and increased to 3.31±0.5 g/100 mg at 180 min (n = 5, P < 0.05) to yield a mean glycogen synthetic rate of 0.34 μg/min/g liver-min.

The $^{13}$C APE in the C1-C6 positions of the glucosyl unit of glycogen and the C1 position of portal vein glucose can be seen in Table I. As we (6) and others (23-27) have previously demonstrated starting with C1 labeled glucose, most of the label in glycogen appears in the C1 position of the glucosyl unit. In addition there is very little difference in the labeling pattern between the 90- and 180-min values for either the $^{13}$C percent labeling in the different positions of the glucosyl units of glycogen or in the portal vein C1 glucose $^{13}$C enrichment (Table I); these findings indicate that steady conditions had been reached by ~90 min, and is consistent with our previous observations (6). The percent contribution of glucose to glycogen formation by the direct pathway (i.e., glucose → glucose-6-P → glucose-1-P → UDP-glucose → glycogen) can be determined by using the mean $^{13}$C percent labeling data in Table I and was found to be 334%.

A representative $^{13}$C-NMR spectra of intrahepatic alanine, lactate, glutamate, and aspartate is shown in Fig. 2 (obtained under conditions described in Methods). As can be seen, the C2 and C3 positions for alanine, lactate, aspartate, and the C2, C3
Table I. Percent Labeling for C1-C6 Glucose (GL1-GL6) in Glycogen, Portal Vein C1 Glucose (GL1p) and C3 Lactate (L3p) Obtained at 90 min and 180 min

<table>
<thead>
<tr>
<th>Glycogen glucose</th>
<th>Portal vein</th>
<th>Portal vein</th>
</tr>
</thead>
<tbody>
<tr>
<td>90' (n = 6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GL1</td>
<td>GL2</td>
<td>GL3</td>
</tr>
<tr>
<td>24.2±4.0</td>
<td>1.0±0.3</td>
<td>0.4±0.1</td>
</tr>
<tr>
<td>180' (n = 5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30.3±3.0</td>
<td>1.1±0.2</td>
<td>0.3±0.1</td>
</tr>
<tr>
<td>Overall mean</td>
<td>26.6±2.7</td>
<td>1.0±0.2</td>
</tr>
</tbody>
</table>

All values expressed in APE±SEM.

and C4 positions of glutamate can easily be discerned. The peak integrals reflect the relative $^{13}$C percent labeling in the respective positions. From these spectra the $^{13}$C labeling in the different positions of alanine, lactate and glutamate can be determined (Eq. 2) and are shown in Table II. The average enrichments at the C2 and C3 positions at 90 min were 2.2±1.0 (A2), 17.4±1.8 (A3) APE, respectively, for alanine, and 2.9±0.5 (L2) and 19.4±1.3 (L3) APE, respectively, for lactate. At 180 min the enrichments in positions 2 and 3 had not changed appreciably: 2.2±0.5 (A2) and 20.5±0.8 (A3) APE, respectively, for alanine and 1.6±0.4 (L2) and 24.0±1.7 (L3) APE, respectively, for lactate.

The enrichments for the C2 and C3 positions of glutamate were 6.1±1.2 (G2) and 3.3±0.7 (G3) APE, respectively, at 90 min and 6.1±0.9 (G2) and 5.0±0.8 (G3) APE, respectively, at 180 min. Of note was the observed increase in C4 from 4.6±1.4 (G4) APE at 90 min to 7.9±1.3 (G4) APE (P < 0.05) at 180 min reflecting an increase in pyruvate dehydrogenase flux (see Discussion) and a slight increase in C3 alanine and lactate enrichments. Of further note was the ratio of C2 glutamate/C3 glutamate. If malate equilibrates completely with fumarate this ratio would be 1. As calculated from the mean data in Table II the C2 glutamate/C3 glutamate ratio is 1.8 at 90 min and 1.2 at 180 min, suggesting that equilibration between malate and fumarate is not complete. This disequilibration is also reflected and in fair agreement with the ratio of enrichment in C6 glucose/C5 glucose being 1.9 at 90 min and 1.5 at 180 min, although any futile cycling of label from glucose down to the level of the triose phosphates and back up into glycogen will further increase this ratio above that due to disequilibration between malate and fumarate. In five animals (90 min; n = 2, 180 min; n = 3) the mean intrahepatic enrichments of C2 and C3 aspartate were determined to be 3.2±0.6 APE and 5.1±1.6 APE, respectively.

From these data the intrahepatic dilution factor for alanine and lactate as they pass through the OAA pool can be determined by Eq. 3. At 90 min the dilution factor was calculated to be 2.5±0.4 and at 180 min 2.3±0.2 (P < NS).

Using a mean value of 2.4 for the dilution factor in conjunction with the $^{13}$C labeling data in positions C5 and C6 glucose (Table I) and C2 and C3 of alanine and lactate (Table II), the percent contribution of alanine plus lactate to newly synthesized glycogen was calculated by Eq. 4 to be 55%.

It should be noted that it is assumed that the enrichments of the metabolites that we measure in the liver extracts represent the enrichments of the metabolites inside the hepatocyte since hepatocytes represent ~ 78% of the parenchymal volume (28). Since glutamate and aspartate are > 24 times more concentrated in the intracellular space than the extracellular space (29) > 99% of the glutamate/aspartate signal must reflect intracellular enrichments of these metabolites. For lactate (and to some degree alanine), which exist in similar concentrations in blood and the hepatocyte, there will be a larger contribution of the extracellular compartment. Assuming the extracellular space of the liver is ~ 16% (28) from our portal vein and liver extract data for lactate $^{13}$C enrichments (Tables I and II), it can be calculated that our intrahepatic enrichments for lactate (Table II) would be over-

Figure 2. Typical $^{13}$C-NMR spectra acquired at 500 MHz of semipurified alanine, lactate, aspartate, and glutamate obtained from a PCA extract of liver as described in Methods.
estimated by, at most, 9%, which would then cause an under-
estimation of the contribution of lactate to glycogen synthesis
by this much.

**Discussion**

It is now becoming apparent that after glucose ingestion in rat
and man only one-third of glycogen repletion occurs directly
from glucose (glucose → glucose-6-P → glucose-1-P → UDP-
glucose → glycogen). We (6), as well as others (1–5, 7, 8), have
demonstrated that the majority of glycogen formation is derived
from a gluconeogenic pathway, possibly from lactate and alanine.
However, the precise contribution of these gluconeogenic pre-
cursors to glycogen synthesis has been difficult to quantitate be-
cause of problems in measuring the dilution of label in pyruvate
as it traverses the oxaloacetate pool. In the present study we
examined this question by employing NMR spectroscopy in
conjunction with $^3$H and $^{14}$C tracer techniques in the awake,
unstressed rat.

In order to determine the amount of dilution that occurs
from labeled pyruvate as it passes through the OAA pool, it is
necessary to isolate from the liver OAA or an intermediate that
equilibrates with OAA. At present, it is very difficult to accurately
determine the labeling pattern of $^{13}$C in OAA from liver extracts.
However, the labeling pattern in OAA may be estimated by
measuring the labeling pattern of glutamate assuming during
steady state the labeling pattern in glutamate reflects the labeling
pattern in alpha-ketoglutarate and assuming the latter equili-
brates with OAA. The fact that the enrichments we obtained
for C2 and C3 aspartate closely matched those for C3 and C2
of glutamate supports this assumption since aspartate directly
equilibrates with OAA via aspartate aminotransferase. As can
be seen from Fig. 3, carbon atoms in positions 2 and 3 of glu-
tamate are derived from carbon atoms 3 and 2 of alanine/lactate.
Therefore, by comparing the enrichment of carbon atoms 2 and
3 of glutamate with carbon atoms 2 and 3 of alanine, an estimate
of the dilution of label from pyruvate as it passes through the
OAA pool can be determined (Eq. 3). Using this line of reasoning
and the data in Table II it can be determined that the dilution
factor at 90 min was 2.5±0.4 and at 180 min was 2.3±0.2 (P < NS).
It is unclear why this estimate is so much larger than the
1.38 estimate of Hetenyi (10). Although Hetenyi's factor was
calculated for [2-$^{14}$C] pyruvate, and our pyruvate was predomi-
nantly labeled in the C3 position, the factor for C3 pyruvate is
in nearly all conditions less than that for C2 pyruvate (11). The
differences between the factors may be related to the different
conditions under which the animals were studied. Our animals
were assessed in a conscious state under conditions of hypergly-
cemia and hyperinsulinemia, whereas his animals were studied
under anesthesia in a “not fasted” state. It should also be pointed
out that our model directly assesses the dilution factor and takes
into account the anaplerotic fluxes of glutamate and glutamine
into the TCA cycle as well as flux through PDH and PK, which
may affect the dilution factor whereas Hetenyi's model does not.
From this estimate of the dilution factor and knowledge the $^{13}$C
labeling pattern in positions C5, C6 of glucose and C2, C3 of
alanine/lactate, it can be calculated from Eq. 4 that $\sim 55%$
of liver glycogen is derived from alanine/lactate.

From the present experimental data the amount of glucose
incorporated into glycogen by the direct pathway can also be
calculated. Thus, knowing the enrichment in the C1 position
of glucose of glycogen and in the C1 position of portal vein glucose,
it can be determined from Eq. 1 that $\sim 34%$ of liver glycogen
is formed by the direct pathway. This is in close agreement with
our previously published results (6) and those of others (1–5).
A maximum estimate of recycling of glucose → triose-phos-
phate → glycogen can also be made from data in Table I as
described previously (6) and was found to be < 2%, which agrees
with our previous findings (6).

Under steady state conditions the $^{13}$C labeling pattern in C2
to C4 of glutamate in conjunction with the enrichment in
positions 2 and 3 of alanine and lactate can be used to estimate
the relative fluxes through pyruvate dehydrogenase/TCA cycle
flux and pyruvate kinase/total pyruvate utilization flux (see Ap-
pendix). Pyruvate dehydrogenase flux was calculated to repre-
sent 24±6% of the total TCA cycle flux at 90 min and increased
slightly but not significantly to 35±5% ($P = 0.18$) of the TCA
cycle flux at 180 min. This increase in flux most likely represents
the further time-related activation of pyruvate dehydrogenase
by insulin after 90 min (30). It should be remembered that these
animals were studied after a 24-h fast when pyruvate dehydro-
genase activity might be expected to be minimal.
An estimate of pyruvate kinase flux/total pyruvate utilization was also obtained as described in the Appendix and was found to be between 51±6% and 31±6% at 90 and 180 min, respectively. This reflects a relatively large amount of intrahepatic recycling between phosphoenolpyruvate and pyruvate and is comparable to the data of Friedmann et al. (31) and Rognstad et al. (32) in fed animals in which pyruvate kinase flux was found to be 40–50% of the gluconeogenic flux in perfused rat liver and isolated hepatocytes. However, it should also be noted that malic enzyme can also scramble label from the C3 position of pyruvate into the C2 position that might therefore result in an overestimation of pyruvate kinase flux by this method.

In summary, after glucose ingestion in a 24-h fasted rat direct conversion of glucose to glycogen accounts for approximately one-third of glycogen formation; the average dilution factor for labeled alanine and lactate as they traverse the oxaloacetate pool under the conditions of this study was 2.4; using this dilution factor it can be calculated that alanine and lactate via the gluconeogenic pathway accounts for ~55% of glycogen formation; together alanine/lactate (55%), glucose (34%) can account for almost all of the glycogen formed; pyruvate dehydrogenase flux ranges between 24 and 35% of total acetyl-CoA production; and pyruvate kinase flux relative to total pyruvate utilization was ~40%.

Appendix

Single pool model steady state equations for: (refer to Fig. 3).

1. Derivation of pyruvate dehydrogenase flux/TCA cycle flux

Assumptions: 1. No appreciable label entering the TCA cycle from free fatty acid oxidation.
   2. Flux into acetyl-CoA from free fatty acids + c = e (total acetyl-CoA production = TCA cycle flux, minimum estimate)
   3. P3 = L3 = A3
   4. Ac2 = G4

\[ \text{PDH flux} = \frac{e - \text{Ac2}}{G4} \]  \[ \text{TCA flux} = \frac{e}{L3} \]

where: P3; L3; A3 = intrahepatic pyruvate; lactate and alanine enrichments (APE) in carbon position 3.

2. Derivation of pyruvate kinase flux/total pyruvate utilization flux:

Assumptions: 1. O2 = (G2 + G3)/2
   2. P2 = L2
   3. Negligible label in extracellular C2 pyruvate/alanine/lactate (i.e., negligible amount of gluconeogenesis occurring extraplastically)
   4. Pyruvate kinase flux is much greater than malic enzyme flux.

\[ \text{PK flux} = \frac{(j)}{(c + g + i)} \]

where \( c + g + l = \text{total pyruvate utilization} \).


